Starling Oncology, Inc.: shareholders and insiders

STLNNASDAQHealthcare · Services-Offices & Clinics of Doctors of Medicine

Price

$3.20

November 18, 2026Market cap $316M

What Ploutos Investor adds for Starling Oncology

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 52% since Nov 5, 2026, when the 10-Q these figures come from was filed ($6.70 then, $3.20 on Nov 18, 2026). The figures date from before that move.10-Q

Insiders and their shares

Purchases and sales by officers and directors from Nov 19, 2025 to Nov 17, 2026, from their own Form 4 filings.

20 Form 4s

Bought on the market

$2.9M

1 person

Sold on the market

$14M

5 people

From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan18%
  • The rest82%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·bought $2.9M by 1 person·sold $14M by 5 people

  • 2025: no buys, sold $50.3K by 1 person
  • 2026: bought $2.9M by 1 person, sold $14M by 5 people
  • Nov 12, 2026Yale PodnosChief Medical Officer
    Kind
  • Nov 9, 2026Jorey Chernett
    Kind
  • Nov 6, 2026Jorey Chernett
    Kind
  • Aug 21, 2026Brad HivelyDirector
    Kind10b5-1
  • Aug 14, 2026Jorey Chernett
    Kind
  • Jul 27, 2026Mohit KaushalDirector
    Kind
  • Jul 27, 2026Anne McGeorgeDirector
    Kind
  • Jul 27, 2026Mark L PacalaDirector
    Kind
  • Jul 27, 2026Mark StolperDirector
    Kind
  • Jul 27, 2026Kimberly Jo TzoumakasDirector
    Kind
  • Jul 27, 2026Brad HivelyDirector
    Kind
  • Jul 27, 2026Karen Marie JohnsonDirector
    Kind
  • Jul 21, 2026Jorey Chernett
    Kind
  • Jul 14, 2026Yale PodnosChief Medical Officer
    Kind10b5-1
  • Jul 14, 2026Yale PodnosChief Medical Officer
    Kind10b5-1
  • Jul 14, 2026Yale PodnosChief Medical Officer
    Kind10b5-1
  • Jul 14, 2026Yale PodnosChief Medical Officer
    Kind10b5-1
  • Jul 10, 2026Jorey Chernett
    Kind
  • Jul 7, 2026Kimberly Jo TzoumakasDirector
    Kind
  • Jul 7, 2026Mark StolperDirector
    Kind
  • Jun 23, 2026Jorey Chernett
    Kind
  • Jun 8, 2026Yale PodnosChief Medical Officer
    Kind10b5-1
  • Jun 4, 2026Jorey Chernett
    Kind
  • May 20, 2026Jorey Chernett
    Kind
  • May 19, 2026Jorey Chernett
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 5, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by STLN's officers and directors from 2021 up to November 18, 2025, 5 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

1 Holders over 5%May 15, 2026 Latest filing
  • Chernett Jorey
    Share of class10.2%
Fell to 5% or less (4)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • M33 Growth I L.P.13D4.94%May 15, 202613D/A
  • FOG Ventures Investments, LLC0.00%Jun 24, 202513G/A
  • Ravi Sarin13D4.70%Apr 23, 202513D/A
  • FMR0.00%Dec 6, 202413G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Renaissance Technologies
    In the quarter-14%
  • Point72 (Cohen)
    In the quarter
  • Citadel Advisors (Griffin)
    In the quarter+11%
  • Millennium Mgmt (Englander)
    In the quarter+546%
  • AQR Capital
    In the quarter+11%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 6.61% of its shares outstanding were held short, -3.8% since the report before.

Shares held short
6.54M
6.61%
Since the report before6.79M on Sep 30, 2026
-3.8%
5.6
1.16M
More days to cover thanof 4,578 US-listed companies with enough volume
67%
Report date
Oct 15, 2026
  • Aug 14, 2026: Shares held short 6.88M
  • Aug 31, 2026: Shares held short 6.82M
  • Sep 15, 2026: Shares held short 7.05M
  • Sep 30, 2026: Shares held short 6.79M
  • Oct 15, 2026: Shares held short 6.54M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading22.1% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 22.1% of the shares in the reported trades were short sales, against 59.3% in the 14 before.

Last 14 sessionsOct 30, 2026 – Nov 18, 2026
22.1%
The 14 beforeOct 12, 2026 – Oct 29, 2026
59.3%
Change
-37.2 pts
Short sales a dayon average, of 2.98M shares
659.4K
More than atof 3,656 US-listed companies, same days
1%
Median of alleight in ten from 34.4% to 63.7%
50.3%
  • Oct 12, 2026: Short sales 66.6%
  • Oct 13, 2026: Short sales 36.4%
  • Oct 14, 2026: Short sales 44.5%
  • Oct 15, 2026: Short sales 54.5%
  • Oct 16, 2026: Short sales 50.7%
  • Oct 19, 2026: Short sales 73%
  • Oct 20, 2026: Short sales 58.4%
  • Oct 21, 2026: Short sales 81%
  • Oct 22, 2026: Short sales 65.1%
  • Oct 23, 2026: Short sales 72.8%
  • Oct 26, 2026: Short sales 53.5%
  • Oct 27, 2026: Short sales 62.5%
  • Oct 28, 2026: Short sales 62%
  • Oct 29, 2026: Short sales 62.9%
  • Oct 30, 2026: Short sales 67.6%
  • Nov 2, 2026: Short sales 70.4%
  • Nov 3, 2026: Short sales 68.8%
  • Nov 4, 2026: Short sales 61.4%
  • Nov 5, 2026: Short sales 64.7%
  • Nov 6, 2026: Short sales 22.7%
  • Nov 9, 2026: Short sales 23.6%
  • Nov 10, 2026: Short sales 18.4%
  • Nov 11, 2026: Short sales 30.4%
  • Nov 12, 2026: Short sales 18%
  • Nov 13, 2026: Short sales 5.7%
  • Nov 16, 2026: Short sales 30.7%
  • Nov 17, 2026: Short sales 19.7%
  • Nov 18, 2026: Short sales 24.6%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

21.51M Insiders' shares21.76% Of the company
  • M33 Growth I GP LLCDirector,TenPercentOwner
    Directly7.93M
  • Jorey ChernettTenPercentOwner
    Directly7.86M
  • Richard A BaraschDirector
    Directly–
  • Daniel VirnichChief Executive Officer
    Directly724.4K
  • Brad HivelyDirector
    Directly412.0K
  • Anne McGeorgeDirector
    Directly332.5K
  • Mihir ShahChief Financial Officer
    Directly327.6K
  • Karen Marie JohnsonDirector
    Directly319.4K
  • Mark L PacalaDirector
    Directly61.9K
  • Yale PodnosChief Medical Officer
    Directly258.8K
  • Robert Ross CarterChief Financial Officer
    Directly235.1K
  • Mohit KaushalDirector
    Directly205.7K
  • Jeremy CastleChief Operating Officer
    Directly90.4K
  • Mark StolperDirector
    Directly57.0K
  • Toi Hc I, LlcTenPercentOwner
    Directly–
  • Kimberly Jo TzoumakasDirector
    Directly46.3K
  • Havencrest Healthcare Partners, L.P.TenPercentOwner
    Directly–

A lower bound: it counts only the 17 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

2 ETFs holding it0.01% The largest weight (VTWO)
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.01%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.01%

2 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

120 Managers, Q2 2026$218M Value of their positions
  • Q3 2025: Managers 108
  • Q4 2025: Managers 117
  • Q1 2026: Managers 115
  • Q2 2026: Managers 120

Institutional investors by quarter

The fund managers holding STLN, quarter by quarter, from Q3 2021 to Q2 2025, 16 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 120 managers held 40.09M shares, worth $218M. During the quarter 27 opened a position, 22 closed one, 49 added and 25 trimmed.

The largest holders, Q2 2026

  • BlackRock
    In the quarter+7.5%
  • Deerfield Management
    In the quarter
  • Vanguard Capital Management
    In the quarter-6.1%
  • Josh Arnold Investment Consultant
    In the quarter
  • Geode Capital Management
    In the quarter+8.1%
  • Goldman Sachs Group
    In the quarter+28%
  • Wexford Capital
    In the quarter
  • State Street
    In the quarter+6.3%
  • Nuveen
    In the quarter×14.8
  • Renaissance Technologies
    In the quarter+51%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Starling Oncology's filings show?

Who buys and sells is one part of Starling Oncology's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about STLN's shareholders

Didn't find what you were looking for?

Ask us
Have STLN's insiders bought or sold?

From Jun 5, 2026 to Nov 17, 2026 Starling Oncology's insiders bought $584.7K and sold $14M of shares on the market. 16% of the sales were under set 10b5-1 plans.

Which well-known managers hold STLN?

5 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $7.4M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.